Berberine and celecoxib synergistically suppress non-small cell lung cancer with EGFR/AKT/COX-2-related signaling: network pharmacology, molecular docking and experimental validation
Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality, and safer combination strategies with improved antitumor efficacy are still needed. Berberine (BBR), a natural isoquinoline alkaloid with multi-target pharmacological activity, and celecoxib (CXB), a selective cyclooxygenase-2 (CO...